Truist Securities Maintains Buy on Elevance Health, Raises Price Target to $475

Benzinga Newsdesk www.benzinga.com Positive 67.1%

Neg 0% Neu 0% Pos 67.1%

Truist Securities analyst David Macdonald maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $450 to $475.